how are glp 1 drugs made GLP-1 GLP-1 Receptor Agonists as Treatments
Description
With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health
National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)
Further studies are needed to assess the potential cardiovascular and renal benefits of combination therapy and to determine suitable patient population for the therapy
While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives
Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied
A needle-free option, 100% online.
